| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'R1' found in 1 term [] and 39 definitions []
| previous 6 - 10 (of 40) nextResult Pages : [1] [2 3 4 5 6 7 8] | | | | Searchterm 'R1' was also found in the following services: | | | | |
| | |
| |
|
Drug Information and Specification
T2, Predominantly negative enhancement
PHARMACOKINETIC
Intravascular
CONCENTRATION
29.8 mg Fe/mL
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
Cardiovascular
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
| | | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'R1' was also found in the following service: | | | | |
| | |
| |
|
Drug Information and Specification
T1, Predominantly positive enhancement
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
DOSAGE
0.1 mmol/kg / 0.2mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
PRESENTATION
Vials of 5, 10, 15, 20mL Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
France, Switzerland
Artirem®
for sale
| | | | • View the DATABASE results for 'Dotarem®' (7).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Some dyamides are under preclinical development as intravascular MRI contrast agents for blood flow perfusion.
Short name: Dy-DTPA-BMA, generic name: Sprodyamide, central moiety: Dy2+, contrast effect: T2*enhanced, relaxivity: r1=3.4, r2=3.8, B0=0.47,
Short name: Dy-DTPA, central moiety: Dy2+, contrast effect: T2*enhanced,
Short name: Albumin-(Dy-DTPA)x, central moiety: Dy2+, contrast effect: T2*enhanced.
| | | | | Further Reading: | Basics:
|
|
| |
| | | Searchterm 'R1' was also found in the following services: | | | | |
| | |
| |
|
A brand name for ferumoxide (same as Feridex®)
Endoremâ„¢ is a black to reddish-brown aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Endoremâ„¢ is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
See also Ferumoxide.
Drug Information and Specification
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
CONCENTRATION
11.2mg Fe/ml
PREPARATION
Suspend in an isotonic glucose solution
DEVELOPMENT STAGE
For sale
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
EU Brazil
Endorem™
for sale
| | | | • View the DATABASE results for 'Endorem™' (5).
| | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'R1' was also found in the following service: | | | | |
| | |
| |
|
A brand name for ferumoxide (same as Endorem™)
Feridex® is a sterile aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Feridex® is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
Feridex® is a black to reddish-brown aqueous colloid.
See also Ferumoxide. In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex.
Drug Information and Specification
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
CONCENTRATION
11.2mg Fe/ml
PREPARATION
Suspend in an isotonic glucose solution
DEVELOPMENT STAGE
For sale
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
| | | | • View the DATABASE results for 'Feridex®' (9).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |